Board of Directors

stig hansen
Dr. Stig Hansen, Co-founder and Chief Executive Officer, holds an M.S. in biochemistry and a Ph.D. in molecular and cell biology from the University of Copenhagen, Denmark. He conducted the majority of his Ph.D. studies at UC Berkeley and was a Novartis Fellow of the Life Sciences Research Foundation at UC Berkeley, where he studied mammalian brain development. In 2000, Dr. Hansen joined Sunesis Pharmaceuticals, where he was instrumental in applying Sunesis technology to the drug discovery process. During his 8 years at Sunesis, Dr. Hansen advanced to Associate Director of Biology and led programs in metabolic disease, auto-immunity, and oncology, participating in two programs that entered clinical development. In addition, Dr. Hansen managed research partnerships with Johnson & Johnson and Biogen Idec, and through participation in numerous partnering discussions he gained significant business development experience. Dr. Hansen also led the committee for new target initiatives and served on the Research Operations Team overseeing all research from project initiation through Phase II. An author on more than 20 patent applications and scientific publications Dr. Hansen oversees Carmot’s biology research.
daniel erlanson

Dr. Daniel Erlanson, Co-founder and VP of Chemistry, holds a Ph.D. in chemistry from Harvard University and gained post-doctoral experience at Genentech. He joined Sunesis Pharmaceuticals at its inception in 1998. At Sunesis, Dr. Erlanson further honed his medicinal chemistry skills on a variety of targets including proteases, phosphatases and kinases. He was key in developing fragment-based drug discovery technologies that formed the basis for numerous corporate partnerships, including inventorship of a fragment-based technology that attracted more than $150 million in partner revenue and equity investments. During his 10 years at the company he advanced to Associate Director of Medicinal Chemistry, leading a team of up to 10 scientists and research associates pursuing multiple targets. Dr. Erlanson is an inventor on more than a dozen issued and published patent applications and is author and presenter of dozens of publications and national and international scientific presentations, including co-editing two books on fragment-based drug discovery. Dr. Erlanson oversees Carmot’s chemistry research.

tim kutzkey
Tim Kutzkey, PhD, joined The Column Group in 2007 and has since contributed to the conception, formation, and management of many of the firm’s portfolio companies. He currently serves as a Board Director of Peloton Therapeutics, a company he launched in 2010, as the interim President and CEO. In addition to Peloton, Dr. Kutzkey serves as a member of the Board of Directors of both Nurix and Carmot Therapeutics and is a Board Observer at Igenica. Dr. Kutzkey was formerly a scientist at KAI Pharmaceuticals, focused on the discovery and development of selective protein kinase C inhibitors. Prior to KAI, he worked at UC Berkeley as a graduate student and postdoctoral scholar in the lab of Dr. Robert Tjian, completing his Ph.D. in 2005. Dr. Kutzkey was previously educated at Stanford University. In addition to Carmot Therapeutics, Dr. Kutszkey also serves on the boards of Peloton Therapeutics and Nurix.
larry lasky

Larry Lasky, PhD, joined The Column Group in 2014. Dr. Lasky is an expert in biotechnology, a field that he has worked in commercially for over 32 years. In 1981, he was a founding scientist of Genetics Institute (acquired by Wyeth), one ofthe earliest biotechnology companies. He was subsequently a leading scientist at Genentech for 20 years, where he worked in various disciplines including vaccinology, immunology, stem cell biology, cellular signaling mechanisms, and monoclonal antibody therapy of tumors. He is a co-author on over 135 publications and a co-inventor on 37 issued and pending patents, several of which generate significant licensing royalties. He was a standing member of the Research Review Committee that directed research across all product areas at the company. He also attained the company’s highest scientific position, Genentech Fellow, in 1995.

As a general partner at Latterell Venture Partners from 2002 to 2007, Larry was instrumental in the founding of Proteolix (acquired by Onyx), Oncomed (nasdaq: OMED), and Cellective Pharmaceuticals (acquired by Medimmune). During his tenure at USVP, he co-founded Intellikine Pharmaceuticals (acquired by Millennium/Takeda), Calithera Pharmaceuticals, Cleave Pharmaceuticals and eFFECTOR pharmaceuticals, where he also serves on the board of directors.

Aetna Wun Trombley

Aetna Wun Trombley, PhD, joins Carmot Therapeutics Board of Directors as an independent director. She is Vice President, Chief Operating Officer of NGM Biopharmaceuticals. She joined NGM as head of Business Development in 2011. She was most recently from Novartis in Basel, Switzerland, where she was Chief of Staff for the Chief Executive Officer and worked on key corporate initiatives and strategic projects across the company’s healthcare businesses. Previously, she was Associate Director, Business Development at XenoPort, Inc. (NASDAQ: XNPT), where her responsibilities also included strategic and portfolio planning in addition to various out-licensing projects. Prior to XenoPort, she was a Senior Engagement Manager at McKinsey & Company, where she advised pharmaceutical and medical device clients on strategic, commercial and operational issues. She received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from MIT.